Apellis Pharmaceuticals, Inc.
pegcetacoplan
geographic atrophy (GA)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on pegcetacoplan for geographic atrophy (GA) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“regulatory submission for prefilled syringe planned in the first half of 2026.”